Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

NCT05001737 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Macrophage Activation Syndrome
Secondary Hemophagocytic Lymphohistiocytosis
Still Disease
Systemic Lupus Erythematosus
SJIA
AOSD
MAS

Interventions

DRUG: Emapalumab

Sponsor

Swedish Orphan Biovitrum